A5010249839- COVID-19 Clinical Research Studies
- SARS-CoV-2 and COVID-19 Research
- COVID-19 Impact on Reproduction
- Extracellular vesicles in disease
- Long-Term Effects of COVID-19
- Cell Adhesion Molecules Research
- MicroRNA in disease regulation
- Viral Infections and Vectors
- RNA Interference and Gene Delivery
- COVID-19 and Mental Health
- Complement system in diseases
Mayo Clinic
2020-2024
Mayo Clinic in Arizona
2020
Stony Brook Medicine
2017-2019
Although severe coronavirus disease 2019 (COVID-19) and hospitalization associated with COVID-19 are generally preventable among healthy vaccine recipients, patients immunosuppression have poor immunogenic responses to vaccines remain at high risk of infection SARS-CoV-2 hospitalization. In addition, monoclonal antibody therapy is limited by the emergence novel variants that serially escaped neutralization. this context, there interest in understanding clinical benefit convalescent plasma...
0 Abstract In the absence of effective countermeasures, human convalescent plasma has been widely used to treat severe acute respiratory syndrome coronavirus 2 including among patients with innate or acquired immunodeficiency. However, association between COVID-19-associated mortality in immunodeficiency and therapeutic use is unknown. We review clinical features treatment protocols COVID-19 after plasma. also discuss time course recovery. These insights provide evidence for need develop a...
Despite the established role of integrin β4 (ITG β4) in breast cancer progression, importance endocytic recycling ITG and its regulatory mechanism are poorly understood. Here, we found that a sub-population is sorted into early endosomes, recycled back to plasma membrane, secreted form extracellular vesicles (EVs) upon EGF treatment triple negative (TNBC) cells. A metastasis suppressor, ARRDC3 (arrestin domain-containing 3) prevents EGF-driven by inducing NEDD4-dependent ubiquitination...
ABSTRACT Although severe coronavirus disease 2019 (COVID-19) and hospitalization associated with COVID-19 are generally preventable among healthy vaccine recipients, patients immunosuppression have poor immunogenic responses to vaccines remain at high risk of infection SARS-CoV-2 hospitalization. Additionally, monoclonal antibody therapy is limited by the emergence novel variants that serially escaped neutralization. In this context, there interest in understanding clinical benefit...